Technologies

COVID-19 Technology

Title:

Protein sub-unit vaccine

Area:

COVID-19 Technology

Focus Area:

Protein subunit Vaccine, COVID Vaccine

Status:

Market Launch

Social Benefits:

Excellent safety profile and the most affordable vaccine that can be produced locally at high capacity suitable for any future pandemics

Developing Agency:

Hyderabad, Telangana (https://www.biologicale.com)

Technology Readiness Index:

TRL-9

Brief Description

Description :

India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine for COVID-19, CORBEVAX, developed by Biological E Limited, is a “recombinant protein sub-unit” vaccine developed from the Receptor Biding Domain (RBD) of the spike protein on the virus’s surface is adjuvanted with CpG 1018 and alum, which helps the body to build the immune response against the virus.

Related Technologies